JAK2 and cancer: Btk silencing effectively reduced the expression of the Janus kinase 2 (JAK2)/STAT3 pathway, which in turn suppressed the survival of cancer cells through Sox-2 and BCL-XL genes and, finally, restored responsiveness to cisplatin.